SeaStar Medical Holding Corporation (ICU) 10-Year Financial Performance & Capital Metrics

ICU • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutSeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.Show more

Revenue $135K
EBITDA -$25M -12191.5%
Net Income -$25M +5.3%
EPS (Diluted) -6.63 +78.1%
Gross Margin 100%
EBITDA Margin -18209.63%
Operating Margin -13216.3%
Net Margin -18392.59%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -73.12 -456.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 97 (top 3%)

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM1195.59%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM54.88%

EPS CAGR

10Y-

5Y-

3Y-

TTM86.88%

ROCE

10Y Avg-352.82%

5Y Avg-352.82%

3Y Avg-

Latest-

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	135K
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	0	0	0	135K
Gross Margin %	-	-	-	-	1%
Gross Profit Growth %	-	-	-	-	-
Operating Expenses+	6.45M	4.45M	11.61M	14.21M	17.98M
OpEx % of Revenue	-	-	-	-	133.16%
Selling, General & Admin	2.43M	1.68M	6.92M	8.04M	8.87M
SG&A % of Revenue	-	-	-	-	65.72%
Research & Development	4.03M	2.77M	2.5M	5.97M	9.11M
R&D % of Revenue	-	-	-	-	67.44%
Other Operating Expenses	0	0	2.19M	200K	0
Operating Income+	-6.45M	-4.45M	-11.61M	-14.21M	-17.84M
Operating Margin %	-	-	-	-	-132.16%
Operating Income Growth %	-	0.31%	-1.61%	-0.22%	-0.26%
EBITDA+	0	-4.38M	-11.56M	-200K	-24.58M
EBITDA Margin %	-	-	-	-	-182.1%
EBITDA Growth %	-	-	-1.64%	0.98%	-121.92%
D&A (Non-Cash Add-back)	6.45M	0	0	14.01M	0
EBIT	-6.45M	-4.38M	-11.56M	-25.15M	-24.58M
Net Interest Income+	-3.31M	-212K	-629K	-1.08M	-143K
Interest Income	0	0	630	0	101K
Interest Expense	3.31M	212K	630K	1.08M	244K
Other Income/Expense	3.19M	-148K	-580K	-12.02M	-6.99M
Pretax Income+	-3.27M	-4.6M	-12.19M	-26.23M	-24.83M
Pretax Margin %	-	-	-	-	-183.9%
Income Tax+	9K	-1K	1K	0	3K
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-3.28M	-4.6M	-12.19M	-26.23M	-24.83M
Net Margin %	-	-	-	-	-183.93%
Net Income Growth %	-	-0.4%	-1.65%	-1.15%	0.05%
Net Income (Continuing)	-3.28M	-4.6M	-12.19M	-26.23M	-24.83M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.01	-8.81	-23.38	-30.26	-6.63
EPS Growth %	-	-880%	-1.65%	-0.29%	0.78%
EPS (Basic)	-0.01	-8.81	-23.38	-30.26	-6.63
Diluted Shares Outstanding	521.64K	521.64K	521.34K	866.81K	3.74M
Basic Shares Outstanding	521.64K	521.64K	521.32K	866.81K	3.74M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.91M	601K	1.52M	2.31M	3.77M
Cash & Short-Term Investments	2.81M	510K	47K	176K	1.82M
Cash Only	2.81M	510K	47K	176K	1.82M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	58K	0	0	112K
Days Sales Outstanding	-	-	-	-	302.81
Inventory	55K	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	0	12K	0	0
Total Non-Current Assets+	2K	2K	1.52M	1.21M	892K
Property, Plant & Equipment	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	2K	2K	1.52M	1.21M	892K
Total Assets+	2.91M	603K	3.04M	3.51M	4.66M
Asset Turnover	-	-	-	-	0.03x
Asset Growth %	-	-0.79%	4.04%	0.16%	0.33%
Total Current Liabilities+	1.08M	3.12M	16.15M	13.05M	6.84M
Accounts Payable	382K	85K	1.93M	4.37M	3.05M
Days Payables Outstanding	-	-	-	-	-
Short-Term Debt	20K	2.38M	1.18M	4.74M	574K
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	0	471K	10.8M	2.41M	33K
Current Ratio	2.69x	0.19x	0.09x	0.18x	0.55x
Quick Ratio	2.64x	0.19x	0.09x	0.18x	0.55x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	73.41M	299K	7.65M	4.34M	0
Long-Term Debt	63K	244K	7.65M	4.34M	0
Capital Lease Obligations	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	73.35M	55K	0	0	0
Total Liabilities	74.49M	3.42M	23.8M	17.38M	6.84M
Total Debt+	83K	2.62M	8.83M	9.08M	574K
Net Debt	-2.72M	2.11M	8.78M	8.9M	-1.25M
Debt / Equity	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-1.95x	-20.99x	-18.43x	-13.15x	-73.12x
Total Equity+	-71.58M	-2.82M	-20.76M	-13.87M	-2.18M
Equity Growth %	-	0.96%	-6.37%	0.33%	0.84%
Book Value per Share	-137.23	-5.40	-39.82	-16.00	-0.58
Total Shareholders' Equity	-71.58M	-2.82M	-20.76M	-13.87M	-2.18M
Common Stock	0	1K	1K	5K	2K
Retained Earnings	-71.72M	-76.31M	-88.5M	-114.73M	-139.56M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	0	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.57M	-5.11M	-7.79M	-10.29M	-16.01M
Operating CF Margin %	-	-	-	-	-118.57%
Operating CF Growth %	-	0.08%	-0.52%	-0.32%	-0.56%
Net Income	-3.28M	-4.6M	-12.19M	-26.23M	-24.83M
Depreciation & Amortization	0	0	0	0	0
Stock-Based Compensation	0	0	1.31M	1.93M	887K
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	-3.19M	162K	533K	11.14M	6.94M
Working Capital Changes	890K	-680K	2.55M	2.88M	992K
Change in Receivables	0	0	4K	12K	-112K
Change in Inventory	137K	55K	0	0	0
Change in Payables	225K	-297K	1.55M	2.44M	-1.28M
Cash from Investing+	0	0	0	0	0
Capital Expenditures	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	105.57M	0	0	0
Cash from Financing+	4.89M	2.82M	7.33M	10.41M	17.65M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	0	-6.15M	272K	4.62M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-5.57M	-5.11M	-7.79M	-10.29M	-16.01M
FCF Margin %	-	-	-	-	-118.57%
FCF Growth %	-	0.08%	-0.52%	-0.32%	-0.56%
FCF per Share	-10.68	-9.80	-14.95	-11.87	-4.28
FCF Conversion (FCF/Net Income)	1.70x	1.11x	0.64x	0.39x	0.64x
Interest Paid	1K	0	6K	1.13M	553K
Taxes Paid	1K	0	1K	0	3K

Key Ratios

Metric	2020	2021	2022	2023	2024
Gross Margin	-	-	-	-	100%
Net Margin	-	-	-	-	-18392.59%
Interest Coverage	-1.95x	-20.99x	-18.43x	-13.15x	-73.12x
FCF Conversion	1.70x	1.11x	0.64x	0.39x	0.64x

Frequently Asked Questions

Growth & Financials

SeaStar Medical Holding Corporation (ICU) reported $0.9M in revenue for fiscal year 2024.

SeaStar Medical Holding Corporation (ICU) grew revenue by 0.0% over the past year. Growth has been modest.

SeaStar Medical Holding Corporation (ICU) reported a net loss of $13.7M for fiscal year 2024.

Dividend & Returns

SeaStar Medical Holding Corporation (ICU) had negative free cash flow of $14.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener